Navigating the Complexities of Cell and Gene Therapy Manufacturing

The 2024 DIA conference, a session about gene therapy manufacturing chaired by Dr. Fouad Atouf, Senior Vice President of Global Biologics at the US Pharmacopeia (USP), brought together leading experts to discuss the multifaceted challenges and solutions in the manufacturing and regulatory landscape of cell and gene therapies (CGT). The session featured presentations from Dr. Michael Day, Senior Director of Regulatory Science at VCLS, and Dr. Haritha Vallabhaneni, Biological Reviewer at the FDA. The discussions underscored the critical need for robust solutions across the entire supply chain of CGT, from raw material procurement to patient administration, emphasizing the importance of addressing risks at each step to ensure the quality and safety of biological medicines.

Industry Perspective: Challenges in Quality Development

Dr. Michael Day provided an industry-centric view on the challenges faced in the quality development of CGT products. He noted that many novel therapies originate from academic settings or small startups, often lacking Good Manufacturing Practice (GMP) processes. Transitioning these early-stage developments into scalable, regulatory-compliant products involves significant hurdles. For instance, a small startup might have developed a promising gene therapy using non-GMP processes in a university lab. When scaling up, they need to ensure that their methods are compatible with GMP standards, which might involve significant changes in their manufacturing process. Contract manufacturers can provide the necessary expertise to bridge this gap, ensuring that the methods used at the lab level can be effectively translated to a larger scale without compromising quality.

Developing a regulatory framework that includes validated safety, identity, and impurity testing as the product progresses through clinical phases is crucial. Dr. Day illustrated this with the example of a cell therapy product moving from preclinical to clinical stages. Safety testing might be limited to basic toxicity studies in the early stages. However, as the product moves into Phase 1 and Phase 2 clinical trials, more rigorous testing for identity and impurities becomes necessary. When the product reaches the Biologics License Application (BLA) or Marketing Authorization Application (MAA) stage, the manufacturing process must be fully validated, and all in-process tests and release tests must be thoroughly documented and validated. Dr. Day stressed the importance of creating a Target Product Profile (TPP) and a Quality Target Product Profile (QTPP) to guide the development process. These documents help outline the desired characteristics, safety, and efficacy profiles and provide a strategic roadmap for regulatory submissions.

FDA Perspective: Raw Material Qualification

Dr. Haritha Vallabhaneni focused on the FDA’s perspective regarding selecting and qualifying raw materials in CGT manufacturing. She underscored the critical role of raw material quality in ensuring the safety and efficacy of the final product. A strong qualification program should assess the inherent toxicity, immunogenicity, and potential for contamination of raw materials. Dr. Vallabhaneni provided an example of a cell therapy product that uses a growth factor derived from animal sources. The risk assessment would need to consider the potential for immunogenic reactions in patients and the risk of contamination with adventitious agents like viruses or prions. The manufacturer must implement rigorous testing and purification processes to mitigate these risks.

Manufacturers are advised to use the highest quality reagents available, preferably FDA-approved or clinical-grade. However, the responsibility for ensuring the quality and suitability of these materials lies with the manufacturers. Dr. Vallabhaneni highlighted the example of a cell culture medium used in manufacturing. Even if the medium is labeled as clinical grade, the manufacturer must verify its quality through testing and documentation. This might include obtaining certificates of analysis from the supplier, performing additional in-house testing, and ensuring the medium is free from contaminants. Dr. Vallabhaneni also highlighted the recent draft guidance from the FDA on using human and animal-derived materials in CGT manufacturing, urging stakeholders to provide comments to refine these guidelines. She explained that the guidance aims to clarify the regulatory expectations for raw material qualification, helping manufacturers navigate the complex landscape of CGT development.

Bridging the Gap: From Lab to Market

Both speakers emphasized the importance of collaboration between developers and regulatory bodies to navigate the complexities of CGT manufacturing. Dr. Day pointed out that contract manufacturers can offer valuable insights into quality systems and analytical methodologies. For example, a small biotech company developing a novel gene therapy might partner with a contract manufacturer with extensive CGT production experience. This partnership can help the biotech company optimize its manufacturing process, develop robust analytical methods, and ensure compliance with regulatory requirements. Dr. Vallabhaneni highlighted the FDA’s willingness to work with sponsors to address unique challenges. She provided an example of a gene therapy product that uses a novel vector with no established animal model for safety testing. In such cases, the FDA is open to alternative approaches, such as in vitro testing or surrogate models, as long as the sponsor can provide a solid scientific rationale and robust data to support the product’s safety.

The speakers also discussed the importance of a well-documented approach to bringing safe and effective cell and gene therapy to market. Dr. Day emphasized the need for a comprehensive Target Product Profile (TPP) and Quality Target Product Profile (QTPP) to guide the development process. These documents help outline the desired characteristics, safety, and efficacy profiles and provide a strategic roadmap for regulatory submissions. Dr. Vallabhaneni added that detailed documentation, including certificates of analysis and origin, is essential. Manufacturers should also provide information on donor testing and any purification processes used. This ensures that the raw materials are safe and suitable for use in the manufacturing process. The insights shared by Dr. Day and Dr. Vallabhaneni underscore the importance of a collaborative, well-documented approach to bringing safe and effective cell and gene therapy to market.

Summary

The session provided a comprehensive overview of the critical aspects of CGT manufacturing, from quality control and regulatory compliance to raw material qualification. The insights shared by Dr. Day and Dr. Vallabhaneni underscore the importance of a collaborative, well-documented approach to bringing safe and effective cell and gene therapies to market. As the field of CGT continues to evolve, ongoing dialogue between industry experts, regulatory bodies, and manufacturers will be essential to overcome the challenges and harness the full potential of these groundbreaking therapies.